Arrhythmias & electrophysiology
Non-early catheter ablation vs drug therapy in atrial fibrillation: Results from the CABANA trial
Authors' conclusion
Non-early AF patients may benefit from catheter ablation similar to early AF patients.
Study context
- Population
- Patients with atrial fibrillation (AF) in CABANA, by non-early (onset of AF ≥1 year) vs early AF1,122 with non-early AF
- Participants
- 2,178 patients
- Comparison
- Catheter ablation vs drug therapy in non-early AF
- Primary endpoint
- Composite of:
- Death
- Disabling stroke
- Serious bleeding
- Cardiac arrest
Primary result
As reported in the abstract
Primary composite, by AF timing (subgroup)
Ablation vs Drug therapyAdjusted hazard ratio (95% CI)P value
Non-early AF
0.83(0.53–1.30)
P = 0.413Early AF
0.78(0.52–1.16)
P = 0.220Secondary outcomes
| Outcome | aHR (95% CI) | P value | |
|---|---|---|---|
| All-cause mortality (non-early AF)Relative reduction 26% | 0.74 (0.42–1.33) | P = 0.314 | |
| All-cause mortality or CV hospitalization (non-early AF)Relative reduction 23% | 0.77 (0.65–0.91) | P = 0.002 | |
| All-cause mortality or CV hospitalization (non-early AF, excluding prior HF) | 0.78 (0.65–0.93) | P = 0.005 | |
| 0.512Adjusted hazard ratio (log scale) |
Original publication
Non-early catheter ablation vs drug therapy in atrial fibrillation: Results from the CABANA trial. Heart Rhythm. Published 9 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →